Upbeat top-line data for New York-based Iveric Bio Inc.'s phase IIb trial testing Zimura in dry age-related macular degeneration propelled the company stock (NASDAQ:ISEE) 82.8% upward in Monday's trading, a big success in a company that rebranded itself earlier this year.
